{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+Long-Acting+Beta+Agonist&page=3",
    "query": {
      "intervention": "Inhaled Long-Acting Beta Agonist",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+Long-Acting+Beta+Agonist&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inhaled+Long-Acting+Beta+Agonist&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T04:03:04.999Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01248208",
      "title": "FluMist in Egg Allergic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Egg Allergy",
        "Eligible for Vaccination Against Influenza"
      ],
      "interventions": [
        {
          "name": "FluMist intranasal influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intramuscular influenza injection (\"flu shot\")",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Walter Reed Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 17,
      "start_date": "2010-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248208"
    },
    {
      "nct_id": "NCT01899742",
      "title": "The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Umeclidinium/Vilanterol 62.5/25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 497,
      "start_date": "2014-09-15",
      "completion_date": "2015-07-22",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 3,
      "location_summary": "Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01899742"
    },
    {
      "nct_id": "NCT02251379",
      "title": "Environmental Control as Add-on Therapy in Childhood Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Flovent Diskus",
          "type": "DRUG"
        },
        {
          "name": "Home Environmental Intervention",
          "type": "OTHER"
        },
        {
          "name": "Advair Diskus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 155,
      "start_date": "2014-10-01",
      "completion_date": "2018-11",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02251379"
    },
    {
      "nct_id": "NCT05689983",
      "title": "Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Nonadherence, Medication"
      ],
      "interventions": [
        {
          "name": "Maintenance ICS and Symptom Driven SABA",
          "type": "DRUG"
        },
        {
          "name": "Symptom-driven budesonide/formoterol combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2022-04-01",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05689983"
    },
    {
      "nct_id": "NCT01017952",
      "title": "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "GW642444 Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1635,
      "start_date": "2009-09-25",
      "completion_date": "2011-10-17",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tallassee",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017952"
    },
    {
      "nct_id": "NCT03930732",
      "title": "Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Dupilumab SAR231893",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Corticosteroid",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Long-Acting Beta Agonist",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Long-Acting Muscarinic Antagonist",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 939,
      "start_date": "2019-04-15",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 51,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03930732"
    },
    {
      "nct_id": "NCT01854047",
      "title": "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ICS/LABA therapy",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol/albuterol",
          "type": "DRUG"
        },
        {
          "name": "Levosalbutamol/levalbuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 776,
      "start_date": "2013-06",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 50,
      "location_summary": "Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854047"
    },
    {
      "nct_id": "NCT05569421",
      "title": "A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A: BGF MDI HFO",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: BGF MDI HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 108,
      "start_date": "2022-10-11",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05569421"
    },
    {
      "nct_id": "NCT01355991",
      "title": "Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James J. Peters Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-08",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 2,
      "location_summary": "West Orange, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01355991"
    },
    {
      "nct_id": "NCT01209715",
      "title": "Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone /salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2014-08-01",
      "last_synced_at": "2026-10-17T04:03:04.999Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209715"
    }
  ]
}